ETF Opportunities Trust Cultivar ETF (BATS: CVAR)

Ultime notizie per ETF Opportunities Trust Cultivar ETF (BATS:CVAR)

Industrials

Basic Materials

Financial Services

Technology

Consumer Defensive

Healthcare

Utilities

Consumer Cyclical

Communication Services

Real Estate

Energy

Other

To achieve its investment objective, the Fund invests primarily in equity securities traded on U.S. exchanges of any size that the Funds investment adviser, Cultivar Capital, Inc. (the Adviser), believes are under-valued, or under-appreciated, by other participants in the broader equity market. In selecting securities for the Fund, the Adviser screens on an ongoing basis the Funds investment universe seeking such securities using an initial valuation assessment that is primarily quantitative, based on cash flow. The Advisers discounted cash flow model uses several key inputs to assess each securitys estimated intrinsic value.

Healthcare Services Group Inc

Core Laboratories Inc

Proto Labs Inc

Southwest Airlines Co.

Newmont Corp.

Barrick Gold Corporation

Cultivar ETF

ETF Opportunities Trust Cultivar ETF

Benchmark analyst Michael Legg reiterates ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) with a Buy and maintains $3 price target.

News

Price Target

Reiteration

Analyst Ratings

CHPT

Benchmark Reiterates Buy on ChargePoint Hldgs, Maintains $3 Price Target

As of Nov. 20, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Energizer Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>)</h3>
<ul>
<li>On Nov. 19, Energizer Holdings reported better-than-expected fourth-quarter adjusted EPS results. &#8220;We finished fiscal 2024 with solid performances across both Battery and Auto Care, driving adjusted earnings growth above our initial expectations,&#8221; said Mark LaVigne, President and Chief Executive Officer. The company's stock gained around 15% over the past month and has a <a href="https://www.benzinga.com/quote/ENR">52-week high of $39.21</a>.</li>
<li>RSI Value: 88.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ENR Price Action: Shares of Energizer gained 9.1% to close at $37.25 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Freshpet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>)</h3>
<ul>
<li>On Nov. 4, Freshpet reported better-than-expected third-quarter financial results and raised its full-year adjusted EBITDA outlook. &#8220;Our third quarter results demonstrate the strength and consistency of both net sales and profitability growth we have been striving to deliver. We delivered our 25th consecutive quarter of >25% year on year net sales growth and matched that with a very strong operating performance. This further strengthens our confidence in our ability to meet or exceed our 2027 goals,&#8221; commented Billy Cyr, Freshpet&#8217;s Chief Executive Officer. The company's stock gained around 14% over the past month and <a href="https://www.benzinga.com/quote/FRPT">has a 52-week high</a> of $159.12.</li>
<li>RSI Value: 72.43</li>
<li>FRPT Price Action: Shares of Freshpet gained 3.9% to close at $156.38 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Cal-Maine Foods Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>)</h3>
<ul>
<li>On Oct. 1, the company posted better-than-expected quarterly earnings. Sherman Miller, president and chief executive officer of Cal-Maine Foods, stated, &#8220;Our financial and operating results for the first quarter mark a strong start to fiscal 2025 for Cal-Maine Foods. These results reflect favorable demand for shell eggs during most of the quarter and significantly higher market prices compared with the first quarter last year.&#8221; The company's stock gained around 4% over the past month and has a <a href="https://www.benzinga.com/quote/CALM">52-week high</a> of $96.02.</li>
<li>RSI Value: 70.14</li>
<li>CALM Price Action: Shares of Cal-Maine gained 1.3% to close at $95.14 on Tuesday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CALM

FRPT

Top 3 Risk Off Stocks That May Collapse This Quarter

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e7ca1775f2b9b000115fded/dominick-gabriele">Compass Point analyst Dominick Gabriele</a> initiated coverage on Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Buy rating and announced a price target of $278. Fiserv shares closed at $215.12 on Tuesday. See how other analysts view this stock.</li>
<li>Bernstein initiated coverage on CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Market Perform rating and announced a price target of $145. Cava Group shares closed at $141.25 on Tuesday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Compass Point analyst Dominick Gabriele initiated coverage on Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Buy rating and announced a price target of $49. Toast shares closed at $42.50 on Tuesday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac4af2b85e930001e6383f/samik-chatterjee">JP Morgan analyst Samik Chatterjee </a>initiated coverage on Ingram Micro Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Neutral rating and announced a price target of $28. Ingram Micro shares closed at $22.78 on Tuesday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst James Callahan initiated coverage on AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with an Overweight rating and announced a price target of $400. AppLovin shares closed at $321.19 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying APP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="521" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20082704/image-208-1024x521.png" alt="" class="wp-image-656899" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20082704/image-208-1024x521.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20082704/image-208-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20082704/image-208-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20082704/image-208.png 1297w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>

Initiation

CAVA

INGM

TOST

This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an&nbsp;abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st &amp; 22nd 2024, in Barcelona Spain.
The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with Long COVID.

Biotech

General

BIVI

BioVie To Present Design Of Planned Phase 2 Study Of Bezisterim For The Treatment Of Long COVID At The Demystifying Long COVID International Conference

<a href="https://www.wolferesearch.com/eventsandconferences/" title="https://www.wolferesearch.com/eventsandconferences/">https://www.wolferesearch.com/eventsandconferences/</a>

Hess CEO Says Between President-Elect Trump And China, Demand For Oil Will Be Stronger Next Year

WIIM

ARGX

Argenx shares are trading higher after the company announced the decision to continue development of efgartigimod subcutaneous in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies.

BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS&#x2122;)&nbsp;in patients with peripheral neuropathic pain. The results were published in the Neuromodulation journal, in a peer-reviewed <a href="https://www.globenewswire.com/Tracker?data=mXgOL4BnKoHbbstEk2zPvBpsiBp_O3Bgt3QvUcTeZWpQ_rRTtxB8WuQoCgOOtILF_DClycQR4U4uhgzUVjYjN4o5yphTX2X2iYd8xoAPn8Acw5_vgLstSmgUCJ0hrDhOrd-xMafK96FCUPLXp1mbBA==">article</a> entitled, "H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain and Symptoms of Anxiety and Depression in Patients with Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover Study."
The double-blind, randomized crossover trial included seventeen (17) patients with chronic neuropathic pain. Participants were assigned to either an active Deep TMS or sham treatment arm for a five-day period, followed by a nine-week washout, before crossing over to the other arm. The study's primary outcome measure was a comparison between the patterns of the active and sham groups' self-reported changes in pain levels from baseline. Secondary outcomes included changes in pain ratings at specific time points in the two arms, as well as changes in comorbid symptoms experienced by the patients, including, for example, anxiety and depression.&nbsp;
Results showed that Active deep-TMS therapy significantly reduced "usual pain intensity" in patients with chronic peripheral neuropathic pain compared to sham treatment and improved symptoms of anxiety and depression in the same patient population.

BWAY

BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A Peer-Reviewed Article Entitled, "H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain And Symptoms Of Anxiety And Depression In Patients With Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover Study."

Stifel analyst Adam Borg maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $300 to $375.

CRWD

Stifel Maintains Buy on CrowdStrike Holdings, Raises Price Target to $375

Barclays analyst Brandt Montour maintains Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Overweight and raises the price target from $43 to $49.

Barclays Maintains Overweight on Viking Holdings, Raises Price Target to $49

Nokia shares are trading higher after the company was awarded a multi-year, multi-billion USD extension deal to deploy 4G and 5G equipment across Indian cities and states.

Stifel analyst Matthew Smith maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Buy and raises the price target from $67 to $81.

BRBR

Stifel Maintains Buy on BellRing Brands, Raises Price Target to $81

Barclays analyst Jiong Shao maintains Trip.com Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) with a Overweight and raises the price target from $76 to $84.

TCOM

Barclays Maintains Overweight on Trip.com Group, Raises Price Target to $84

CHWY

Chewy shares are trading higher after B of A Securities upgraded the stock from Underperform to Buy and raised its price target from $24 to $40.

Stifel analyst Stephen Gengaro downgrades DMC Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) from Buy to Hold and lowers the price target from $16 to $8.

Downgrades

BOOM

Stifel Downgrades DMC Glb to Hold, Lowers Price Target to $8

Benchmark analyst Bruce Jackson reiterates Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) with a Speculative Buy and maintains $1.25 price target.

MLSS

Benchmark Reiterates Speculative Buy on Milestone Scientific, Maintains $1.25 Price Target

KEYS

Keysight Techs shares are trading higher after the company reported better-than-expected Q4 financial results. Also, multiple firms raised their respective price targets on the stock.

Company growth continues in support of high-performance compute customers
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fcorescientific.com%2F&amp;esheet=54155709&amp;newsitemid=20241120134811&amp;lan=en-US&amp;anchor=Core+Scientific+Inc.&amp;index=1&amp;md5=76f2b34d9aeda6f0fcb62d21ab645f03">Core Scientific Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) ("Core Scientific" or the "Company"), a leader in digital infrastructure for high-performance computing and bitcoin mining, today announced the Denton City Council's approval of amendments to the Company's Power Purchase Agreements and land leases. The approval came during the Council's November 19 meeting.

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Announces The Denton City Council's Approval Of Amendments To The Company's Power Purchase Agreements And Land Leases

Stifel analyst Selman Akyol maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Buy and raises the price target from $190 to $224.

TRGP

Stifel Maintains Buy on Targa Resources, Raises Price Target to $224

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold.

SAGE

Needham Reiterates Hold on Sage Therapeutics

TVGN

Tevogen Bio Holdings shares are trading higher after the company announced it internally developed an intellectual property portfolio and product assets valued at over $10 billion that does not currently reflect in the balance sheet.

Comments

ETF Opportunities Trust Cultivar ETF

Notizie

Ultime notizie per ETF Opportunities Trust Cultivar ETF (BATS:CVAR)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO